Daily Sepsis Research Analysis
Three studies stood out today: an innovative sialic acid–modified paclitaxel liposome that selectively targets overactivated neutrophils improved survival in a murine model simulating advanced cancer complicated by sepsis; a methods paper showed large language models provide poorly calibrated pre-test diagnostic probabilities for sepsis compared with traditional machine learning; and a large retrospective cohort linked statin use with lower 30-day mortality in sepsis-associated encephalopathy, w
Summary
Three studies stood out today: an innovative sialic acid–modified paclitaxel liposome that selectively targets overactivated neutrophils improved survival in a murine model simulating advanced cancer complicated by sepsis; a methods paper showed large language models provide poorly calibrated pre-test diagnostic probabilities for sepsis compared with traditional machine learning; and a large retrospective cohort linked statin use with lower 30-day mortality in sepsis-associated encephalopathy, with divergent effects by statin type.
Research Themes
- Neutrophil-targeted immunomodulation via nanomedicine in cancer–sepsis comorbidity
- Calibration and reliability of AI for diagnostic probability estimation in sepsis
- Drug repurposing and statin class effects in sepsis-associated encephalopathy
Selected Articles
1. Sialic acid-modified nanomedicines modulate neutrophils for dual therapy of cancer and sepsis: addressing neglected sepsis comorbidities during cancer treatment.
An SA-modified paclitaxel liposome that binds L-selectin on neutrophils selectively depleted hyperactive neutrophils, reduced tissue infiltration, and improved survival in murine melanoma and sepsis models. In a late-stage cancer plus sepsis model, 72-hour survival was 66.7% with PTX-SAL versus 0% with conventional paclitaxel solution, suggesting targeted nanomedicine can mitigate treatment-related immune toxicity while controlling inflammation.
Impact: Introduces a mechanistically targeted, dual-benefit therapy addressing both cancer progression and sepsis by modulating neutrophils, with striking survival gains in a clinically relevant comorbidity model.
Clinical Implications: For oncology patients at high risk for sepsis, neutrophil-targeted nanomedicines could offer anti-tumor efficacy while reducing sepsis-related mortality by avoiding nonspecific immune cytotoxicity. These findings justify translational studies to evaluate safety, dosing, and synergy with antimicrobials and source control.
Key Findings
- PTX-SAL bound L-selectin on neutrophils, selectively eliminating hyperactive neutrophils and blocking their migration.
- In sepsis and melanoma mouse models, PTX-SAL showed superior efficacy and safety versus paclitaxel solution.
- In a late-stage tumor plus sepsis model, 72-hour survival was 66.7% with PTX-SAL, whereas all animals died within 24 hours with paclitaxel solution.
Methodological Strengths
- Use of a novel, clinically relevant dual comorbidity model (advanced cancer with sepsis).
- Mechanism-based targeting (L-selectin binding) with functional readouts (neutrophil migration, survival).
Limitations
- Preclinical animal data; human pharmacokinetics, immunologic effects, and safety remain unknown.
- Comparisons to standard sepsis care (e.g., antibiotics, fluids, vasopressors) were not detailed.
Future Directions: Conduct dose-ranging and safety studies in large animals, explore combination with antimicrobials and source control, and assess immunologic balance (host defense vs. hyperinflammation) in translational trials.
Advanced cancer patients face a high risk of sepsis due to immune suppression and infection susceptibility. To tackle this challenge, we developed an innovative animal model that simulates the clinical scenario of late-stage cancer complicated by sepsis and designed a sialic acid (SA)-modified paclitaxel (PTX) liposome (PTX-SAL). This formulation specifically targets overactivated peripheral blood neutrophils (PBNs) by binding to L-selectin on their surface. It effectively eliminates hyperactive neutrophils and blocks their migration, thus reducing infiltration into tumor and inflammation sites. In sepsis and melanoma mouse models, PTX-SAL demonstrated superior therapeutic efficacy and a favorable safety profile. Notably, in the late-stage tumor model with sepsis, PTX-SAL significantly improved survival rates, with a 72-hour survival rate of 66.7%. In stark contrast, the PTX solution (PTX-S) group exhibited accelerated mortality, with all animals succumbing within 24 h, highlighting the detrimental effects of PTX-S's non-selective cytotoxicity on immune cells. These findings underscore the superior long-term safety and therapeutic advantage of nanomedicines like PTX-SAL over conventional drug formulations. In summary, SA-modified nanomedicines offer a dual benefit by targeting and eliminating inflammatory neutrophils, addressing both tumor progression and sepsis, and significantly reducing mortality in preclinical models. This innovative strategy fills a critical gap in the treatment of advanced cancer complicated by sepsis.
2. Uncertainty estimation in diagnosis generation from large language models: next-word probability is not pre-test probability.
Across three clinical prediction tasks including sepsis, an XGBoost classifier trained on structured EHR data outperformed multiple LLM-based uncertainty estimation methods. LLM Embedding+XGB approached baseline performance, whereas verbalized confidence and token logits were poorly calibrated, emphasizing the need for hybrid models and better calibration for clinical use.
Impact: Provides timely, methodologically clear evidence that LLM confidence signals are not reliable pre-test probabilities for sepsis, guiding safer AI deployment and research toward calibrated hybrid approaches.
Clinical Implications: Do not rely on LLM self-reported confidence to estimate diagnostic probabilities for sepsis. Prefer calibrated models trained on structured data, and consider LLMs as adjuncts (e.g., feature extraction) within hybrid pipelines with explicit uncertainty calibration.
Key Findings
- An XGBoost classifier trained on structured EHR data outperformed LLM-based uncertainty estimation across sepsis, arrhythmia, and CHF tasks.
- LLM Embedding+XGB was the closest to baseline, while Verbalized Confidence and Token Logits underperformed and were poorly calibrated.
- Performance trends were consistent across models and demographic subgroups, underscoring generalizability of the limitation.
Methodological Strengths
- Direct, head-to-head comparison across multiple LLMs, uncertainty methods, and clinical tasks including sepsis.
- Use of standard metrics (AUROC, correlation) and subgroup analyses for robustness.
Limitations
- Single-center dataset with modest sample size (n=660) and binary outcomes.
- Limited set of LLMs and uncertainty methods; not a prospective clinical impact evaluation.
Future Directions: Develop calibrated hybrid pipelines that combine LLM representation with structured-data models, incorporate numerical reasoning, and prospectively validate fairness and calibration in multi-center cohorts.
OBJECTIVE: To evaluate large language models (LLMs) for pre-test diagnostic probability estimation and compare their uncertainty estimation performance with a traditional machine learning classifier. MATERIALS AND METHODS: We assessed 2 instruction-tuned LLMs, Mistral-7B-Instruct and Llama3-70B-chat-hf, on predicting binary outcomes for Sepsis, Arrhythmia, and Congestive Heart Failure (CHF) using electronic health record (EHR) data from 660 patients. Three uncertainty estimation methods-Verbalized Confidence, Token Logits, and LLM Embedding+XGB-were compared against an eXtreme Gradient Boosting (XGB) classifier trained on raw EHR data. Performance metrics included AUROC and Pearson correlation between predicted probabilities. RESULTS: The XGB classifier outperformed the LLM-based methods across all tasks. LLM Embedding+XGB showed the closest performance to the XGB baseline, while Verbalized Confidence and Token Logits underperformed. DISCUSSION: These findings, consistent across multiple models and demographic groups, highlight the limitations of current LLMs in providing reliable pre-test probability estimations and underscore the need for improved calibration and bias mitigation strategies. Future work should explore hybrid approaches that integrate LLMs with numerical reasoning modules and calibrated embeddings to enhance diagnostic accuracy and ensure fairer predictions across diverse populations. CONCLUSIONS: LLMs demonstrate potential but currently fall short in estimating diagnostic probabilities compared to traditional machine learning classifiers trained on structured EHR data. Further improvements are needed for reliable clinical use.
3. Association between statin use and 30-day mortality among patients with sepsis-associated encephalopathy: a retrospective cohort study.
In 2,729 SAE patients from MIMIC-IV, statin use was associated with lower 30-day mortality (HR 0.77), with simvastatin showing the strongest association (HR 0.58) and rosuvastatin associated with higher mortality (HR 1.88). Associations persisted across demographic and severity strata, motivating stratified randomized trials and careful consideration of statin class.
Impact: Suggests class-specific effects of statins in SAE with large, adjusted observational data, informing drug repurposing and trial design in a high-mortality sepsis complication.
Clinical Implications: Clinicians should avoid assuming a class effect of statins in SAE; if statins are used, simvastatin may be preferable while rosuvastatin warrants caution pending randomized evidence. These findings support careful medication reconciliation and prospective trials.
Key Findings
- Overall statin use was associated with reduced 30-day mortality in SAE (HR 0.77, 95% CI 0.66–0.90).
- Simvastatin had the strongest protective association (HR 0.58), while rosuvastatin was associated with increased mortality (HR 1.88).
- Associations were consistent across age, sex, SOFA, SAPS II, and SIRS subgroups.
Methodological Strengths
- Large sample from a high-quality ICU database (MIMIC-IV) with multivariable Cox modeling.
- Extensive subgroup analyses by demographics and illness severity indices.
Limitations
- Observational design with potential residual confounding and confounding by indication.
- Exposure timing, dosing, and adherence details were not fully characterized.
Future Directions: Conduct randomized, stratified trials comparing specific statins in SAE; mechanistic studies to elucidate differential pleiotropic effects on neuroinflammation and endothelial function.
AIM: Sepsis-associated encephalopathy (SAE) is a common and serious complication of sepsis with poor prognosis. Statin was used in SAE patients, whereas its effects on these patients remain unknown. This study is aimed at investigating the impact of statins on the 30-day mortality of patients with SAE. METHODS: In this retrospective cohort study, data from SAE patients were extracted from the Medical Information Mart for Intensive Care IV (MIMIC-IV). Statins include atorvastatin, pravastatin, rosuvastatin, and simvastatin. The outcome was 30-day mortality of SAE patients starting 24 h after the first intensive care unit (ICU) admission and at the first time after hospitalization. Potential covariates (sociodemographic characteristics, vital signs, score indexes, laboratory parameters, comorbidities, and treatment intervention methods) were selected using univariate Cox proportional hazard analysis. Associations between statin use and statin type and 30-day mortality were explored using univariate and multivariate Cox proportional hazard models with hazard ratios (HRs) and 95% confidence intervals (CIs). Associations were further explored in different age groups, sex, sequential organ failure assessment (SOFA), simplified acute physiology score II (SAPS II), and systemic inflammatory response syndrome (SIRS) populations. RESULTS: A total of 2,729 SAE patients were included in the study, and 786 (28.8%) died within 30 days. Statin use was associated with lower odds of 30-day mortality (HR = 0.77, 95%CI: 0.66-0.90) in all SAE patients. Patients who took simvastatin treatments were associated with lower odds of 30-day mortality (HR = 0.58, 95%CI: 0.43-0.78). Rosuvastatin treatments had a higher 30-day mortality risk (HR = 1.88, 95%CI: 1.29-2.75). Statin use was also associated with lower 30-day mortality among patients of different ages, sex, sequential organ failure assessment (SOFA), SAPS II, and SIRS. CONCLUSION: Patients who were treated with simvastatin were associated with lower odds of 30-day mortality in SAE patients. Caution should be paid to statin use in SAE patients, particularly in patients treated with rosuvastatin or pravastatin.